300 likes | 530 Views
TAXUS ATLAS SMALL VESSEL and LONG LESION First Report of Nine-Month Clinical and Angiographic Results . Mark A. Turco, MD, FACC and John A. Ormiston, MBChB On behalf of the TAXUS ATLAS Investigators. Conflict of Interest Disclosures.
E N D
TAXUS ATLAS SMALL VESSEL and LONG LESION First Report of Nine-Month Clinical and Angiographic Results Mark A. Turco, MD, FACC and John A. Ormiston, MBChB On behalf of the TAXUS ATLAS Investigators
Conflict of Interest Disclosures • TAXUS ATLAS SV and LL and production of this presentation were supported by Boston Scientific Corporation (BSC) • The following relationships exist related to BSC and this presentation: • Mark A. Turco: • Research grants and other research support • Consultant • Member of speaker’s bureau • John A. Ormiston: • Research grants and other research support • Consultant • Member of advisory board
Design Improvements in TAXUS Liberté Improved performance 27% reduced stent strut thickness Reduced stent to artery ratio More homogeneous drug distribution 15% more conformable and 15% more flexible 5 wing fold balloon: improved re-wrap and less withdrawal resistance TAXUS Express to TAXUS LibertéEvolution of the TAXUS Technology TAXUS Express TAXUS Liberté TAXUS ATLAS program: Transfer of proven drug/polymerTAXUS technology to the improved Liberté platform
TAXUS ATLAS ProgramEvaluating the TAXUS Liberté Stent Global, Multi-center, Historically Controlled Trials on De Novo Lesions
TAXUS ATLASSmall Vessel TAXUS ATLASLong Lesion TAXUSExpress Non-Inferiority BMSExpress TAXUSExpress Superiority Non-Inferiority TAXUS LibertéTAXUS ATLAS Expansion Program TAXUSLiberté 2.25 mm TAXUS Liberté Long (38 mm)
TAXUS ATLAS Small VesselStudy Flow Intent-to-Treat BMS Control DES Control Express (BMS) N=155 TAXUS Liberté 2.25 N=261 TAXUS Express N=75 • TAXUS V pts with: • RVD≤2.5mm, lesions≤28mm • Single planned 2.5 or 2.25mm study stent • TAXUS V pts with: • RVD≤2.5mm, lesions≤28mm • Single planned 2.25mm study stent 9-Month Follow-Up Express (BMS) N=148 (95%) TAXUS Liberté 2.25 N=257 (98%) TAXUS Express N=72 (96%) 9-Month QCA Follow-Up Express (BMS) N=105 (68%) TAXUS Liberté 2.25 N=212 (81%) TAXUS Express N=55 (73%)
Baseline Characteristics for Small VesselTAXUS Liberté 2.25 versus BMS Control *QCA Data
P<0.0001 BMS Control (N=155) TAXUS Liberté 2.25 (N=261) Primary Endpoint Met for Small VesselTAXUS Liberté 2.25 Superior to BMS Control Late Loss % DS (Analysis Segment)Primary Endpoint In-Stent In-Segment P<0.0001 P<0.0001 45.6±23.5 0.84±0.57 % Diameter Stenosis 0.55±0.55 32.1±18.4 0.28±0.45 0.16±0.40
P=1.00 P=0.78 P=0.0191 P=0.0065 P=1.00 P=1.00 P=0.0001 41% 48% 67% BMS Control (N=155) TAXUS Liberté 2.25 (N=261) 9-Month Clinical Events in Small VesselSignificant TAXUS Liberté Clinical Benefit vs. BMS Patients (%) 1.2 0.7 Cardiac Death Overall MI TLR TVR Remote Overall TVR Overall MACE All Death
TAXUS ATLASSmall Vessel TAXUS ATLASLong Lesion Superiority Met BMSExpress TAXUSExpress TAXUSExpress Superiority Non-Inferiority Non-Inferiority TAXUS LibertéTAXUS ATLAS Expansion Program TAXUSLiberté 2.25 mm TAXUS Liberté Long (38 mm)
Baseline Characteristics in Small VesselTAXUS Liberté 2.25 versus DES Control *QCA Data
Primary Endpoint Met for Small VesselT. Liberté 2.25 non-inferior (superior) to T. Express % Diameter Stenosis (Analysis Segment): ITT Population P<0.0001 for Non-inferiority P=0.0351 for Superiority Pre-specifiedMargin 10.0% 95%Confidence Interval -1.4% 38.4±23.6 32.1±18.4 Difference-6.3% % Diameter Stenosis 95% CI is less than prespecified margin -10% -5% 0 5% 10% T. Express Control T. Liberté 2.25 Difference (T. Liberté – T. Express) Non-inferiority met in ITT population (P<0.0001) T. Liberté 2.25 is Superior to T. Express Control (ITT population) Non-inferiority also demonstrated in per protocol population (P<0.0001)
P=0.02 P=0.69 P=1.00 P=0.02 T. Express Control (N=75) T. Liberté 2.25 (N=261) 9-Month QCA Outcomes in Small VesselSignificant benefit for TAXUS Liberté 2.25 Binary Restenosis (% pts) Late Loss (mm) P=0.03 P=0.0085 0.44±0.61 0.33±0.52 0.28±0.45 0.16±0.40 ProximalEdge In-Stent DistalEdge In-Stent Analysis Segment Paired lesion analysis
38% 43% 58% T. Express Control (N=75) T. Liberté 2.25 (N=261) 9-Month Clinical Events in Small VesselSignificant ClinicalBenefit for TAXUS Liberté P=0.21 P=0.46 P=0.024 P=1.00 P=0.07 P=0.10 P=0.30 Patients (%) 2.7 1.2 Cardiac Death Overall MI TLR TVR Remote Overall TVR Overall MACE All Death
Stent Thrombosis (Per Protocol) in SVSimilar Rates for all 3 Arms Acute &Subacute Late Total ST P= P= 0.22 0.14 1.00 1.00 0.39 0.56 % ST (per protocol) (n=2) (n=2) (n=1) (n=2) (n=1) (n=2) 0 – 30 days 31 – 284 days 0 – 284 days T. Express Control (N=75) T. Liberté 2.25 (N=261) BMS Control (N=155) Rates were identical using ARC Definite/Probable Definition
TAXUS ATLAS Small VesselSummary • Efficacy Outcomes: • Primary endpoint of 9-month % DS (analysis segment) was met: • TAXUS Liberté 2.25 is superior to Express BMS Control • TAXUS Liberté 2.25 is non-inferior (and actually superior) to TAXUS Express Control • Significant reductions in Late Loss and Restenosis with TAXUS Liberté vs. both TAXUS Express and BMS • Significantly reduced TLR in TAXUS Liberté vs. both Controls • Safety Outcomes: • Rates for death, cardiac death, MI, and stent thrombosis for the TAXUS Liberté 2.25 group low and comparable to TAXUS Express and BMS
TAXUS ATLASSmall Vessel TAXUS ATLASLong Lesion Non-Inferiority Met Superiority Met BMSExpress TAXUSExpress TAXUSExpress Superiority Non-Inferiority Non-Inferiority TAXUS LibertéTAXUS ATLAS Expansion Program TAXUSLiberté 2.25 mm TAXUS Liberté Long (38 mm)
TAXUS ATLAS Long LesionStudy Flow T. Express Control T. Liberté 38mm Intent-to-Treat TAXUS Express N=145 TAXUS Liberté N=150 • TAXUS IV and V pts with: • RVD≥2.5 - ≤4.0mm • Lesions ≥26 - ≤34 mm 9-Month Follow-Up TAXUS Express N=138 (95.2%) TAXUS Liberté N=145 (96.7%) 9-Month QCA Follow-Up TAXUS Express N=91 (62.8%) TAXUS Liberté N=126 (84.0%)
Baseline Characteristics in Long LesionTAXUS Libertéused in Complex Populations * QCA Data
Procedural Characteristics * QCA Data
P=0.71 Primary Endpoint Met for Long LesionTAXUS Liberté Non-inferior to TAXUS Express % Diameter Stenosis (Analysis Segment): ITT Population Non-inferiority met Pre-specifiedMargin 6.89% 32.6±19.3 31.7±17.2 95% CI 3.19 Difference-0.93 Analysis Segment % DS 95% CI is less than prespecified margin -1% 0 1% 2% 3% 4% 5% 6% 7% T. Express Control T. Liberté 38 mm Difference (T. Liberté – T. Express) T. Liberté 38 mm is similar to T. Express Control Non-inferiority (P=0.001) Non-inferiority also met in per protocol population (P=0.001) and after propensity adjustment (P<0.0001)
79% T. Express Control (N=145) T. Liberté 38 mm (N=150) 9-Month Clinical Events for Long LesionSignificantly Reduced MI Compared to T. Express P=0.06 P=0.026 P=0.73 P=0.45 P=0.93 P=0.16 P=0.21 Patients (%) 2.8 0.7 Cardiac Death Overall MI TLR TVR Remote Overall TVR Overall MACE All Death
QMI(n=2) P=0.013 P=1.00 NQMI(n=7) NQMI(n=2) Breakdown of MI EventsReduced In-Hospital Non-Q MI in TAXUS Liberté Non-Q-Wave MI In-Hospital Discharge – 9m 4.1% Patients (%) CK-MB≥5x (n=3) CK-MB≥5x (n=2) CK-MB≥5x (n=1) CK-MB≤3 (n=3) 0.0% TAXUSExpress TAXUSLiberté TAXUSExpress TAXUSLiberté
Breakdown of MI EventsSingle vs. Multiple Stents SINGLE STENT MULTIPLE STENTS P=0.0213 P=1.00 Patients (%) (n=6 ) (n=2) (n=3) (n=0) TAXUSExpress(N=67) TAXUSLiberté(N=126) TAXUSExpress(N=78) TAXUSLiberté(N=24)
P=0.24 P=0.49 P=0.24 P=0.49 T. Express Control (N=75) T. Liberté 38mm (N=150) Stent Thrombosis to 9 MonthsNo ST Events with TAXUS Liberté Acute, Subacute(0-30 Days) Late(31-284 Days) Total ST(0-284 days) ProtocolDefinition Patients (%) (n=1) (n=1) ARC*Def/Prob Patients (%) (n=2) (n=2) *Academic Research Consortium
TAXUS ATLAS Long LesionSummary • Efficacy Outcomes: • Primary endpoint of 9-month % DS (analysis segment) was met: • T. Liberté 38 mm non-inferior to T. Express Control • Safety Outcomes: • No cardiac death or stent thrombosis in TAXUS Liberté • Significantly reduced myocardial infarction rate in TAXUS Liberté compared to TAXUS Express, even in single stents • Procedural Observations: • Reduced procedural time and increased procedural success rate compared to TAXUS Express
Primary endpoint met in both studies TAXUS ATLAS SV and LLOverall Summary Clinical Benefits: • SAFETY: Maintained or improved • Similarly low death, MI and ST rates for TAXUS Liberté 2.25mm compared to TAXUS Express • Significantly reduced MI for TAXUS Liberté Long (38mm) compared to TAXUS Express, with comparable death and ST • RESTENOSIS: Reduced • Late Loss, Binary Restenosis Reduced: • In TAXUS Liberté 2.25 mm compared to both BMS and TAXUS Express • TLR Reduced: In T. Liberté 2.25 compared to BMS and T. Express • DELIVERABILITY: Enhanced • Design improvements in TAXUS Liberté platform vs. TAXUS Express • Reduced procedure time
Conclusions • The TAXUS ATLAS Small Vessel and Long Lesion studies demonstrate successful transfer of the paclitaxel technology to the next generation TAXUS Liberté stent. • The new TAXUS Liberté stent design leads to improved clinical outcomes in small vessels and long lesions compared to TAXUS Express.